Back to list

FDA rebuts criticism of government plan to set ADI of ractopamine

2012/04/22 21:30:42

Taipei, April 22 (CNA) An allegedly proposed acceptable daily intake (ADI) of the leanness-enhancing drug ractopamine, which was criticized by several consumer groups Sunday, is just a consensus reached in a food safety evaluation meeting, Food and Drug Administration (FDA) Director-General Kang Jaw-jou said that day.

Access to articles dating back more than six months is not available free of charge. You can gain access by becoming a paid Focus Taiwan member.